Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669773 | 0.81 | HCAR3 (0.40) | HCAR3DRD2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16280198 | 0.81 | HCAR3 (0.40) | HCAR3DRD2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5148332 | 0.81 | SERPINE1 (0.37) | — | |
| SCHEMBL5148377 | 0.78 | RIPK1 (0.39) | RECQLHTTALDH1A1 | |
| SCHEMBL5150109 | 0.78 | CETP (0.35) | — | |
| SCHEMBL5148370 | 0.78 | PSEN1 (0.36) | — | |
| SCHEMBL2262814 | 0.78 | HCAR3 (0.38) | HCAR3CYP2D6CYP2C9CYP2C19RECQL | |
| SCHEMBL5148327 | 0.77 | SERPINE1 (0.36) | — | |
| SCHEMBL1896849 | 0.75 | CETP (0.37) | HCAR3DRD2TP53HTTALDH1A1 | |
| SCHEMBL5148324 | 0.72 | CYP3A4 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | HCAR3 2746/4885DRD2 4569/4885NLRP3 2988/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | HCAR3 1528/4885DRD2 4613/4885NLRP3 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.